Welcome to our dedicated page for SAB Biotherapeutics SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company developing SAB-142 for type 1 diabetes and other autoimmune diseases. Form 8-K disclosures cover clinical presentations, Regulation FD materials, and material agreements, including manufacturing services for SAB-142.
The company’s filings also describe its capital structure and financing activity, including common stock, pre-funded warrants, public offering agreements and shelf registration use. Proxy materials cover annual meeting matters, director elections, board composition, stockholder voting items and related governance disclosures.
SAB Biotherapeutics, Inc. (SABS) filed a prospectus supplement updating the selling stockholder table for an existing resale registration covering up to 250,000,000 shares of Common Stock. These shares are issuable upon conversion of Series B Convertible Preferred Stock and Series B Preferred Stock purchase warrants held by selling stockholders.
The registered shares include 100,000,000 shares issuable upon conversion of Series B Preferred Stock, 100,000,000 shares issuable upon conversion of Enrollment Date Warrant Shares, and 50,000,000 shares issuable upon conversion of Release Date Warrant Shares. The supplement states it is filed solely to reflect a transfer of securities between a selling stockholder and its affiliate, and allows these holders to resell their shares from time to time, subject to 4.99% or 9.99% beneficial ownership blockers in many cases. SABS common stock trades on the Nasdaq Capital Market under the symbol SABS, with a reported closing price of $3.79 per share on August 18, 2026.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of SAB Biotherapeutics, Inc. common stock. The Master Fund directly holds 6,627,501 shares of common stock, representing 7.3% of the class based on 90,986,368 shares outstanding as of August 3, 2026.
Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member of Perceptive Advisors, may each be deemed to beneficially own these shares. All 6,627,501 shares are reported with shared voting and shared dispositive power; no reporting person has sole voting or sole dispositive power.
Caligan Partners LP and David Johnson filed an amended Schedule 13G reporting their beneficial ownership of common stock of SAB Biotherapeutics, Inc. Caligan, as investment manager to certain funds and accounts, and Johnson, as its managing partner, are the reporting persons.
They report beneficial ownership of 7,967,207 shares of SAB Biotherapeutics common stock, representing 8.8% of the class, based on 90,986,368 shares outstanding as of August 3, 2026. All reported shares are held with shared voting and dispositive power; neither reporting person has sole voting or sole dispositive power over these shares.
The filing notes that other persons (the underlying funds and accounts) may have rights to receive dividends or proceeds from the sale of these securities in accordance with the investment structure referenced in Item 2(a). David Johnson signs the report both in his capacity as managing partner of Caligan and in his individual capacity.
Commodore Capital and related filers report a significant ownership position in SAB Biotherapeutics, Inc. As of June 30, 2026, they may be deemed to beneficially own 8,948,170 shares of common stock, representing 9.9% of the class. This position includes 2,870,000 common shares, 5,946,400 shares issuable upon conversion of Series B Preferred Stock, and 131,770 shares issuable upon conversion of Series B Preferred Stock underlying Tranche 1 Warrants. Additional Tranche 1 and Tranche 2 Warrants are contractually limited by a 9.99% Beneficial Ownership Limitation, so those excluded securities are not counted in the reported stake.
SAB Biotherapeutics, Inc. received an amended Schedule 13G indicating that Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC may be deemed to beneficially own 22,637,108 shares of common stock and equivalents, while Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC may be deemed to beneficially own 2,286,301 shares.
These positions include existing common shares plus shares issuable upon conversion of Series B Preferred Stock and upon exercise of related Enrollment Warrants and Data Release Warrants that are exercisable or convertible within 60 days. Each reporting person reports beneficial ownership of 9.99% of the common stock class, with blocking provisions in the preferred stock and warrants that prevent conversions or exercises which would increase ownership above 9.99% of the issuer’s voting securities.
Woodline Partners LP filed an amended Schedule 13G reporting beneficial ownership of 5,455,355 shares of SAB Biotherapeutics, Inc. common stock, including shares issuable upon conversion of preferred stock underlying warrants. This represents 6.8% of the outstanding common stock.
The position consists of 1,180,355 common shares, plus 2,850,000 shares issuable from Series B Preferred Stock underlying Enrollment Warrants and 1,425,000 shares issuable from Series B Preferred Stock underlying Data Release Warrants, all held for Woodline Master Fund LP. The percentage is based on 76,464,094 common shares outstanding as of May 6, 2026. Woodline reports sole voting and dispositive power over the 5,455,355 shares, with the Woodline Fund entitled to dividends and sale proceeds.
Balyasny Asset Management and related entities reported significant ownership in SAB Biotherapeutics, Inc. common stock. Through Atlas Diversified Master Fund, Ltd. and Atlas Private Holdings (Cayman) Ltd., they beneficially own 7,225,439 shares, including 3,465,000 shares issuable upon exercise of 34,650 warrants.
This position represents approximately 9.45% of SAB Biotherapeutics’ 76,464,094 shares outstanding as of May 6, 2026. The warrants are subject to a Beneficial Ownership Limitation that blocks exercises which would result in ownership above 9.99% of outstanding shares.
Adage Capital Management, L.P. and related entities and individuals report beneficial ownership of 6,405,553 shares of SAB Biotherapeutics, Inc. common stock. This represents 8.38% of the company’s outstanding common stock, based on 76,464,094 shares outstanding as of May 6, 2026.
The reporting persons have shared voting and dispositive power over all 6,405,553 shares and no sole voting or dispositive power. The shares are held directly by Adage Capital Partners, L.P., with Adage Capital Management, L.P. as investment manager and Robert Atchinson and Phillip Gross reporting through their managing member roles in related entities.
RA Capital Management, L.P. and affiliated reporting persons report beneficial ownership of 9,609,852 shares of SAB Biotherapeutics, Inc. common stock, representing 9.9% of the class based on 90,986,368 shares outstanding as of August 3, 2026. This amendment reflects a change in ownership percentage due to an increase in SAB’s outstanding shares, not any new acquisitions or dispositions by the group.
The RA Capital Healthcare Fund directly holds 4,401,500 common shares, Series B preferred stock convertible into up to 12,738,500 common shares, preferred stock purchase warrants, and pre-funded warrants exercisable for up to 2,753,246 common shares. A Beneficial Ownership Blocker currently limits the fund and its affiliates from beneficially owning more than 9,609,852 common shares, with a default cap of 9.99%, adjustable up to 19.99% on 61 days’ notice.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing multi-specific human IgG therapies, reported higher operating spending and net losses for the quarter ended June 30, 2026 while strengthening its capital base. The company’s lead asset, SAB-142, is in a registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes.
Total operating expenses for Q2 2026 were $23,377 (in thousands), driven by research and development of $16,172 (in thousands) and general and administrative of $7,205 (in thousands). Net loss for the quarter was $22,491 (in thousands), and for the first six months of 2026 it was $41,360 (in thousands), or $0.62 basic and diluted loss per share.
As of June 30, 2026, the company held cash and cash equivalents of $8,267 (in thousands), short-term investments of $94,365 (in thousands), and long-term investments of $105,346 (in thousands), supporting total assets of $238,210 (in thousands) and stockholders’ equity of $214,785 (in thousands). A March 2026 public offering of common stock and pre-funded warrants generated net proceeds of approximately $88,697 (in thousands). Based on its current operating expense level, management states existing resources are expected to cover operating cash needs for at least twelve months following the report date.